| Vitas Corporation 105 Marquette Street, Suite A, La Salle, IL, 61301 | |
| (815) 220-0021 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.
A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation.
Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg.
If the website malfunctions in October and November were infuriating to supporters of health care reform, the continuing parade of delays that followed it have simply been depressing. They have contributed to the impression that the Obama administration is desperately trying to keep the new system from spinning out of control, countering the good news that 1.2 million people have signed up for insurance through the federal and state exchanges. ... Having cracked once on this subject, the White House will be pushed to do so more forcefully by the law's critics when the policies take effect next month. This should be the last concession (David Firestone, 12/23).
› Verified 2 days ago
| Name | Vitas Corporation |
|---|---|
| Location | 105 Marquette Street, Suite A, La Salle, Illinois |
| Hospice ID | 141531 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 580 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.
A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation.
Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg.
If the website malfunctions in October and November were infuriating to supporters of health care reform, the continuing parade of delays that followed it have simply been depressing. They have contributed to the impression that the Obama administration is desperately trying to keep the new system from spinning out of control, countering the good news that 1.2 million people have signed up for insurance through the federal and state exchanges. ... Having cracked once on this subject, the White House will be pushed to do so more forcefully by the law's critics when the policies take effect next month. This should be the last concession (David Firestone, 12/23).
› Verified 2 days ago
| NPI Number | 1295877843 |
| Organization Name | Vitas Healthcare Corporation Of Illinois |
| Address | 105 Marquette St La Salle, Illinois, 61301 |
| Phone Number | (815)220-0021 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.
A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation.
Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg.
If the website malfunctions in October and November were infuriating to supporters of health care reform, the continuing parade of delays that followed it have simply been depressing. They have contributed to the impression that the Obama administration is desperately trying to keep the new system from spinning out of control, countering the good news that 1.2 million people have signed up for insurance through the federal and state exchanges. ... Having cracked once on this subject, the White House will be pushed to do so more forcefully by the law's critics when the policies take effect next month. This should be the last concession (David Firestone, 12/23).
› Verified 2 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 97.2 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 96.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 85.7 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 66.7 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 91.3 | 97.3 |
| Patients who got timely treatment for shortness of breath | 81.7 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 95.9 | 93.3 |
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.
A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation.
Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg.
If the website malfunctions in October and November were infuriating to supporters of health care reform, the continuing parade of delays that followed it have simply been depressing. They have contributed to the impression that the Obama administration is desperately trying to keep the new system from spinning out of control, countering the good news that 1.2 million people have signed up for insurance through the federal and state exchanges. ... Having cracked once on this subject, the White House will be pushed to do so more forcefully by the law's critics when the policies take effect next month. This should be the last concession (David Firestone, 12/23).
› Verified 2 days ago
| Home Health Aides | 19.5 |
| Counselors | 3 |
| Licensed Practical or Vocational Nurses | 6 |
| Medical Social Workers | 2 |
| Physicians | 2 |
| Registered Nurses | 23 |
| Total Employees | 55.5 |
|---|
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.
A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation.
Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg.
If the website malfunctions in October and November were infuriating to supporters of health care reform, the continuing parade of delays that followed it have simply been depressing. They have contributed to the impression that the Obama administration is desperately trying to keep the new system from spinning out of control, countering the good news that 1.2 million people have signed up for insurance through the federal and state exchanges. ... Having cracked once on this subject, the White House will be pushed to do so more forcefully by the law's critics when the policies take effect next month. This should be the last concession (David Firestone, 12/23).
› Verified 2 days ago
| Others | 13 |
| Total Volunteers | 13 |
|---|
News Archive
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.
A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation.
Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg.
If the website malfunctions in October and November were infuriating to supporters of health care reform, the continuing parade of delays that followed it have simply been depressing. They have contributed to the impression that the Obama administration is desperately trying to keep the new system from spinning out of control, countering the good news that 1.2 million people have signed up for insurance through the federal and state exchanges. ... Having cracked once on this subject, the White House will be pushed to do so more forcefully by the law's critics when the policies take effect next month. This should be the last concession (David Firestone, 12/23).
› Verified 2 days ago
| Vitas Corporation Location: 105 Marquette Street, Suite A, La Salle, Illinois, 61301 Phone: (815) 220-0021 |